The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Open accessAbstract
In vitro-transcribed mRNAs encoding physiologically important proteins have considerable potential for therapeutic applications. However, in its present form, mRNA is unfeasible for clinical use because of its labile and immunogenic nature. Here, we investigated whether incorporation of naturally modified nucleotides into transcripts would confer enhanced biological properties to mRNA. We found that mRNAs containing pseudouridines have a higher translational capacity than unmodified mRNAs when tested in mammalian cells and lysates or administered intravenously into mice at 0.015-0.15 mg/kg doses. The delivered mRNA and the encoded protein could be detected in the spleen at 1, 4, and 24 hours after the injection, where both products were at significantly higher levels when pseudouridine-containing mRNA was administered. Even at higher doses, only the unmodified mRNA was immunogenic, inducing high serum levels of interferon-alpha (IFN-alpha). These findings indicate that nucleoside modification is an effective approach to enhance stability and translational capacity of mRNA while diminishing its immunogenicity in vivo. Improved properties conferred by pseudouridine make such mRNA a promising tool for both gene replacement and vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both of the candidates are pharmacologically optimized 15,16 , N 1 -methylpseudouridine nucleoside-modified mRNAs 17 that are administered intramuscularly in a prime-boost regimen 21”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which is widely believed to be critical to the recent success of mRNA vaccines1,2,10,37,38”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein.”
From Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Substitution of chemically modified nucleotides in messenger ribonucleic acid (mRNA) enhances stability and transfection capability, and decreases immunogenicity1–3”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This can be circumvented by the incorporation of naturally occurring nucleosides and by applying stringent purification to remove double-stranded RNA contaminants (19–21).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [20]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Karikó et al. reported that mRNA with nucleoside modifications were insensitive to ribonuclease L (RNase L) degradation, did not activate TLRs and protein kinase R, which subsequently resulted in improved translational efficiency and stability, compared to unmodified mRNA (20).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Substitution of uridine with m1Ψ in mRNA significantly improves the translation efficiency and decreases innate immunogenicity (20).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a successful approach to avoid overactivation of the innate immunity and increase translation of mRNA is the use of modified nucleosides such as methyl-pseudo uridine.29”
From Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA (2021) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two uridine analogs pseudouridine (Ψ) or 1-methyl-pseudouridine (m1Ψ) are widely used for mRNA therapeutics because they can increase mRNA stability and help modulate the host immune response31,32.”
From Human 5′ UTR design and variant effect prediction from a massively parallel translation assay (2019) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Replacing of uridine by pseudouridine into mRNA gives superior nonimmunogenic mRNA with increased translational capacity and biological stability (20).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Our work principally confirms that conventional unmodified mRNAs are inferior to molecules harboring specific nucleoside modifications as suggested by various recent reports,23,24,25,26,27 however, the picture changes dramatically with a sophisticated sequence-engineering.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Although pseudouridine is primarily found in tRNA, rRNA, and small nuclear RNAs, pseudouridine-containing mRNAs were still translated and produced even more protein compared to unmodified mRNA.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“As mammalian host cells attack unmodified exogeneous RNA [12,13], all U nucleotides were replaced by N1-methylpseudouridine (Ψ) [14,15].”
From Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines (2021) · cites this paper as [12]
In the citing paper
“To avoid this, Karikó and colleagues found that adding modified nucleosides during IVT of mRNA can significantly reduce the host inflammatory response without affecting protein expression.81,159”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [159]
In the citing paper
“Studies have found that replacing original nucleosides with m6A and s2U inhibits activation of TLR3, whereas activation of TLR7 and TLR8 is blocked when using ψ, 5-methyluridine (m5U), m6A, and s2U, thereby inhibiting the innate immune responses and improving protein translation efficiency.81,159,171”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [159]
In the citing paper
“However, the incorporation of modified nucleosides into mRNA can significantly improve the biological stability and translational capacity of the mRNA while decreasing the innate immune response.36, 37, 38”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [37]
In the citing paper
“These alterations possibly lead to a blunted specific immune response.37,133, 134, 135”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [37]
In the citing paper
“Nevertheless, immune responses to IVT mRNA may also suppress antigen expression and negatively affect vaccine efficacy175,180,181.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [180]
In the citing paper
“Taken together, these findings resulted in a paradigm of the design of mRNA formulations for vaccination.One strategy is to use mRNA which is fully optimized to obtain a strong adjuvant effect, another is to work with 'modified' mRNA with high translation capacity, and thus improved antigen bio-availability [43,62].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 4,022
Self-citationSpecies-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Self-citationLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Self-citationLutz, M. B., Kukutsch, N. A., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,972
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citation5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Self-citationRaper, S. E., Chirmule, N. B., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,531
Flagged first, then by citations
1 of the 30 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 901–1,000 of 1,003
The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines
Harris, J. E. (2022) · Health Policy and Technology · doi:10.1016/j.hlpt.2022.100619 · Cited by 16
Delivering the message: How a novel technology enabled the rapid development of effective vaccines
Shapiro, L., & Losick, R. M. (2021) · Cell · doi:10.1016/j.cell.2021.08.019 · Cited by 15
BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology
Hao, S., Inamdar, V. V., Sigmund, E. C., Zhang, F., Stephan, S. B., Watson, C., Weaver, S., Nielsen, U. B., & Stephan, M. T. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.029 · Cited by 15
Innate sensing of mRNA vaccines
Wuebben, C., Bartok, E., & Hartmann, G. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102249 · Cited by 16
Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domainPreprint
Kobiyama, K., Imai, M., Jounai, N., Nakayama, M., Hioki, K., Iwatsuki‐Horimoto, K., Yamayoshi, S., Tsuchida, J., Niwa, T., Suzuki, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.04.433852 · Cited by 15
Qin, Z., Bouteau, A., Herbst, C., & Igyártó, B. Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.16.484616 · Cited by 15
Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance
Tang, L., Tian, H., Min, Q., You, H., Yin, M., Yang, L., Zhao, Y., Wu, X., Li, M., Du, F., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01854-w · Cited by 14
Khan, M., Musazzi, U. M., Manellari, S., Mouawad, N., Damiano, G., Rinaldi, R., Raucci, A., Costantino, S., Paneni, F., Minghetti, P., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107847 · Cited by 16
Danz, H., Dauner, A. L., Sharma, S., Babiceanu, M., Clark, N., Ontiveros, R. J., Amezquita, R. A., Zhilin-Roth, A., Reyes, E., Khoo, C., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01263-1 · Cited by 15
Yadav, P. K., Haruehanroengra, P., Irani, S., Wang, T., Ansari, A., Sheng, J., & Hussain, M. M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101813 · Cited by 14
Ma, Q., Li, R., Guo, J., Li, M., Ma, L., Dai, J., Shi, Y., Dai, J., Huang, Y., Dai, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10101698 · Cited by 13
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Zhang, M., Singh, N., Ehmann, M. E., Zheng, L., & Zhao, H. (2023) · iScience · doi:10.1016/j.isci.2023.107739 · Cited by 16
Large-scale manufacturing of base-edited chimeric antigen receptor T cells
Woodruff, R., Parekh, F., Lamb, K., Mekkaoui, L., Allen, C. G., Smetanova, K., Huang, J. L., Williams, A., Toledo, G. S., Lilova, K., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101123 · Cited by 14
mRNA and Synthesis-Based Therapeutic Proteins: A Non-Recombinant Affordable Option
Niazi, S. K., & Magoola, M. (2023) · Biologics · doi:10.3390/biologics3040020 · Cited by 13
Novel Lipid Nanoparticles Stable and Efficient for mRNA Transfection to Antigen-Presenting Cells
Choi, K. C., Lee, D. H., Lee, J., Lee, J. S., Lee, Y. K., Choi, M. J., Jeong, H. Y., Kim, M. W., Lee, C.-G., & Park, Y. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031388 · Cited by 14
Zhang, Y., Yan, H., Wei, Z. C., Hong, H., Huang, D., Liu, G., Qin, Q., Rong, R., Gao, P., Meng, J., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132433 · Cited by 14
Kayesh, M. E. H., Kohara, M., & Tsukiyama–Kohara, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115909 · Cited by 14
mRNA Vaccine for Alzheimer’s Disease: Pilot Study
Hovakimyan, A., Chilingaryan, G., King, O., Capocchi, J. K., Chadarevian, J. P., Davtyan, H., Kniazev, R., Agadjanyan, M. G., & Ghochikyan, A. (2024) · Vaccines · doi:10.3390/vaccines12060659 · Cited by 15
Non-viral vectors for chimeric antigen receptor immunotherapy
Tretbar, S., Rurik, J. G., Rustad, E. H., Sürün, D., Koehl, U., Olweus, J., Buchholz, F., Ivics, Z., Fricke, S., & Blache, U. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00348-w · Cited by 15
Rationalizing the effects of RNA modifications on protein interactions
Vandelli, A., Broglia, L., Armaos, A., Ponti, R. D., & Tartaglia, G. G. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102391 · Cited by 14
Jia, S., Yu, X., Deng, N., Chen, Z., Ju, M., Wang, F., Zhang, Y., Gao, Z., Li, Y., Zhou, H., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70190 · Cited by 14
Advances in Development of mRNA-Based Therapeutics
Huang, L., Zhang, L., Li, W., Li, S., Wen, J., Li, H., & Liu, Z. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_222 · Cited by 16
Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine
Ping, H., Yu, W., Gong, X., Tong, X., Lin, C., Chen, Z., Cai, C., Guo, K., & Ke, H. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01290-y · Cited by 14
Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination
Sekulovski, M., Mileva, N. B., Vasilev, G., Miteva, D., Gulinac, M., Peshevska-Sekulovska, M., Chervenkov, L., Batselova, H., Vasilev, G., Tomov, L., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102813 · Cited by 14
Michel, T., Kankura, A., Medina, M. L. S., Kurz, J., Behring, A., Avci‐Adali, M., Nolte, A., Schlensak, C., Wendel, H. P., & Krajewski, S. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0537 · Cited by 14
In Vitro Synthesis of Modified RNA for Cardiac Gene Therapy
Sultana, N., Sharkar, M. T. K., Hadas, Y., Chepurko, E., & Zangi, L. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0668-1_21 · Cited by 14
Advances and Strategies in Enhancing mRNA Cancer Vaccines
Zhang, M., Chen, S., Hu, H.-J., Ong, Y., & Ni, Q. (2025) · Advanced Materials · doi:10.1002/adma.202509880 · Cited by 17
Protective RNA nanovaccines against Mycobacterium avium subspecies hominissuis
Touray, B. J. B., Hanafy, M., Phanse, Y., Hildebrand, R., & Talaat, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188754 · Cited by 14
Elamin, M. Y., Maslamani, Y. A., Muaddi, M. A., Alameer, A. A., Alqassim, A. Y., Doweri, A. A., Zaylaee, M. M., Rayani, H. Y., Darraj, A., Hejri, Y. M., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.06.014 · Cited by 13
Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer
Meulewaeter, S., Zhang, Y., Wadhwa, A., Fox, K., Lentacker, I., Harder, K. W., Cullis, P. R., Smedt, S. C. D., Cheng, M. H. Y., & Verbeke, R. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168385 · Cited by 13
Schievelbein, M., Resende, C., Glennon, M. M., Kerosky, M., & Brown, J. A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105548 · Cited by 12
Wang, S., Guo, B., Wang, H., & Yang, F. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105547 · Cited by 14
Implementation of mRNA–Lipid Nanoparticle Technology in Atlantic Salmon (Salmo salar)
Dahl, L. O. S., Hak, S., Braaen, S., Molska, A., Rodà, F., Parot, J., Wessel, Ø., Fosse, J. H., Bjørgen, H., Borgos, S. E., et al. (2024) · Vaccines · doi:10.3390/vaccines12070788 · Cited by 17
1mΨ influences the performance of various positive-stranded RNA virus-based replicons
Miyazato, P., Noguchi, T., Ogawa, F., Sugimoto, T., Fauzyah, Y., Sasaki, R., & Ebina, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-68617-y · Cited by 13
Molecular Dynamics Simulation of Lipid Nanoparticles Encapsulating mRNA
Zhang, Z., Cheng, D., Luo, W., Hu, D., Yang, T., Hu, K., Liang, L., Liu, W., & Hu, J. (2024) · Molecules · doi:10.3390/molecules29184409 · Cited by 13
Advancing vaccine technology through the manipulation of pathogenic and commensal bacteria
Lloren, K. K. S., Senevirathne, A., & Lee, J. H. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101349 · Cited by 13
Fougeroux, C. E., Hagen, S. H., Goksøyr, L., Aves, K.-L., Okholm, A. K., Morin, C., Lokras, A. G., Baghel, S. S., Foged, C., van de Vegte‐Bolmer, M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01889-1 · Cited by 15
Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations
Konopka, E., Edgerton, A. O., & Kutzler, M. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584876 · Cited by 14
Translational recoding by chemical modification of non-AUG start codon ribonucleotide bases
Fujita, Y., Kameda, T., Singh, C. R., Pepper, W., Cecil, A., Hilgers, M., Thornton, M. M., Asano, I., Moravek, C., Togashi, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm8501 · Cited by 13
Zhang, Y., Xi, X., Yu, H., Yang, L., Lin, J., Yang, W., Liu, J., Fan, X., & Xu, Y. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.017 · Cited by 13
Prokhorova, D. V., Vokhtantsev, I. P., Tolstova, P. O., Zhuravlev, E. S., Kulishova, L. M., Zharkov, D. O., & Stepanov, G. A. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0069 · Cited by 13
Machado, R. R. G., Walker, J. L., Scharton, D., Rafael, G. H., Mitchell, B. M., Reyna, R. A., de Souza, W. M., Liu, J., Walker, D. H., Plante, J. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40033-2 · Cited by 15
Duan, M., Dev, I., Lu, A. Y., Ayrapetyan, G., You, M. Y., & Shapiro, M. G. (2024) · Cell Systems · doi:10.1016/j.cels.2024.06.001 · Cited by 15
Hausburg, F., Na, S., Voronina, N., Skorska, A., Müller, P., Steinhoff, G., & David, R. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373957 · Cited by 13
Maurer, J., Vanluchene, H., Tsalmpouris, A., Morreel, K., Camperi, J., Sandra, K., & Guillarme, D. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118309 · Cited by 13
Heiser, B. J., Lewis, M. M., Zerankeshi, M. M., Netemeyer, E. K., Hernandez, A. M., Marras, A. E., & Ghosh, D. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00061k · Cited by 15
Kunyk, D., Plotnikova, M. A., Bespalov, M., Shevyrev, D., Klotchenko, S. A., Ivanov, R. A., & Reshetnikov, V. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188986 · Cited by 17
Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation
Kim, C., Lee, Y., Lee, H., & Kim, B. (2025) · Small Methods · doi:10.1002/smtd.202501401 · Cited by 13
mRNA therapeutics beyond vaccines: dosing precision challenges and clinical translation framework
Niazi, S. K. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00159e · Cited by 12
In Silico Methods, Simulations, and Design of Drug‐Delivery Nanocarriers
Song, X., Liu, P., Zhang, X., Zhou, Y., Qian, H., Yang, K., Zhang, X., Gao, X., Zheng, J., Shi, X., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202523068 · Cited by 13
Process and analytical strategies for the safe production of mRNA vaccines and therapeutics
Nowak, C. J. A., Liu, S., Falconer, R. J., & Gerstweiler, L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11455-0 · Cited by 16
Chatterjee, S., Bhattacharya, M., Lee, S., & Chakraborty, C. (2023) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2023.100150 · Cited by 12
Messenger RNA Therapy for Female Reproductive Health
VanKeulen‐Miller, R., & Fenton, O. S. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00803 · Cited by 13
Assembling the RNA therapeutics toolbox
Teng, M., Xia, Z. J., Lo, N., Daud, K., & He, H. H. (2024) · Medical Review · doi:10.1515/mr-2023-0062 · Cited by 12
Palm, S. M., Horton, C. A., Zhang, X., & Collins, K. (2024) · RNA · doi:10.1261/rna.080031.124 · Cited by 13
Therapeutic applications of cell engineering using mRNA technology
He, Y., Johnston, A. P. R., & Pouton, C. W. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.07.012 · Cited by 12
Warmiński, M., Depaix, A., Ziemkiewicz, K., Śpiewla, T., Zuberek, J., Drążkowska, K., Kędzierska, H., Popielec, A., Baranowski, M. R., Sklucka, M., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae763 · Cited by 12
Microbial Synthesis of Nucleosides: Advances and Prospects
Dai, J., Geng, M., Du, Y., Iqbal, M. W., Yang, H., Shen, X., Wang, J., Sun, X., & Yuan, Q. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00530 · Cited by 12
Niazi, S. K. (2025) · Biomedicines · doi:10.3390/biomedicines13010097 · Cited by 12
Rahman, M. M., Masum, M. H. U., Parvin, R., Das, S. C., & Talukder, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313559 · Cited by 13
RetractedWei, Z., Zhang, S., Wang, X., Xue, Y., Dang, S., & Zhai, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524317 · Cited by 16
Post-transcriptional modular synthetic receptors
Zhang, X., Mille, L. S., Kaseniit, K. E., Lee, A. P., Zhang, M., Call, C. C., Hu, Y., Xie, Y., & Gao, X. J. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01872-w · Cited by 13
Wojcechowskyj, J. A., Jong, R. M., Mäger, I., Flach, B., Munson, P. V., Mukherjee, P. P., Mertins, B., Barcay, K. R., & Folliard, T. (2025) · npj Vaccines · doi:10.1038/s41541-025-01135-8 · Cited by 14
Loss of Pseudouridine Synthases in the RluA Family Causes Hypersensitive Nociception in Drosophila
Song, W., Ressl, S., & Tracey, W. D. (2020) · G3 Genes Genomes Genetics · doi:10.1534/g3.120.401767 · Cited by 12
Muscle Regeneration and RNA: New Perspectives for Ancient Molecules
Buonaiuto, G., Desideri, F., Taliani, V., & Ballarino, M. (2021) · Cells · doi:10.3390/cells10102512 · Cited by 11
The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize
Janowski, M., & Andrzejewska, A. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.003 · Cited by 12
Clinical Development of mRNA Vaccines: Challenges and Opportunities
August, A., Brito, L., Paris, R., & Zaks, T. Z. (2022) · Current topics in microbiology and immunology · doi:10.1007/82_2022_259 · Cited by 12
COVID-19 vaccines and a perspective on Africa
Mantovani, A., Rescigno, M., Forni, G., Tognon, F., Putoto, G., Ictho, J., & Lochoro, P. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.01.005 · Cited by 12
Zhu, Y., Sarıbaş, A. S., Liu, J., Lin, Y., Bodnar, B. H., Zhao, R., Guo, Q., Ting, J., Wei, Z., Ellis, A., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.012 · Cited by 12
Fotoran, W. L., da Silva, J. R., Glitz, C., Ferreira, L. C. D. S., & Wunderlich, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041223 · Cited by 14
Modified mRNA Formulation and Stability for Cardiac and Skeletal Muscle Delivery
Żak, M. M., Kaur, K., Yoo, J., Kurian, A. A., Adjmi, M., Mainkar, G., Yoon, S., & Zangi, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092176 · Cited by 12
Ting, J., Tamayo-Mendoza, T., Petersen, S. R., Reet, J. V., Ahmed, U. A., Snell, N. J., Fisher, J. D., Stern, M., & Oviedo, F. (2023) · Chemical Communications · doi:10.1039/d3cc04705a · Cited by 12
Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences
Rhoads, R. E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3625-0_1 · Cited by 11
Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics
Hirschberger, K., Jarzębińska, A., Kessel, E., Kretzschmann, V. K., Aneja, M. K., Dohmen, C., Herrmann-Janson, A., Wagner, E., Plank, C., & Rudolph, C. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.006 · Cited by 12
Luo, Z., Bian, Y., Zheng, G., Wang, H., Yan, B., Su, W., Dong, W., Hu, Z., Ding, J. H., Wang, A., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.623959 · Cited by 12
Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
Sa-nguanmoo, N., Namdee, K., Khongkow, M., Ruktanonchai, U., Zhao, Y., & Liang, X. (2021) · Nano Research · doi:10.1007/s12274-021-3832-y · Cited by 12
Amplified Production of a DNA Decoy Catalyzed by Intracellular MicroRNA
Yasuda, S., Morihiro, K., Koga, S., & Okamoto, A. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202424421 · Cited by 11
Recent advances in the application of polymeric nanoparticles to the pulmonary delivery of mRNA
Panovich, P. M., Ganesan, A., Angadi, A. R., & Piotrowski-Daspit, A. S. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2509477 · Cited by 12
Salihovic, A., Taladriz‐Sender, A., & Burley, G. A. (2025) · Chemical Science · doi:10.1039/d5sc03026a · Cited by 13
Decrypting the Immune Symphony for RNA Vaccines
Weidensee, B., & Sahu, I. (2025) · Vaccines · doi:10.3390/vaccines13080882 · Cited by 13
Research progress of mRNA vaccines for infectious diseases
Zhang, Z., Du, J., Zhang, D., Han, R., Wu, X., & Liang, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03060-x · Cited by 19
Rochman, Y., Kotliar, M., Klingler, A. M., Rochman, M., Alameh, M., Melamed, J. R., Osswald, G. A., Caldwell, J. M., Felton, J. M., Mack, L. E., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194080 · Cited by 14
Self-citationN1-Methylpseudouridine directly modulates translation dynamics
Rozman, B., Broennimann, K., Rajan, K. S., Nachshon, A., Saha, C., Arazi, T., Mohan, V., Geiger, T., Wollner, C. J., Richner, J. M., et al. (2026) · Nature · doi:10.1038/s41586-025-09945-5 · Cited by 15
The mRNA-Based Innovative Strategy: Progress and Challenges
Zhou, H., Wei, D., Chen, Z., Chen, H., Dong, C., Cai, W., Wang, J., Liu, X., Li, Y., Yang, Y., et al. (2026) · Nano-Micro Letters · doi:10.1007/s40820-025-01906-x · Cited by 17
Luo, Z., Bian, Y., Zheng, R., Song, Y., Li, S., Xu, H., Wang, H., Li, X., Tao, Z., Wang, A., et al. (2022) · Cell Proliferation · doi:10.1111/cpr.13318 · Cited by 11
Wang, F. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03108-6 · Cited by 11
Practical Considerations for Next-Generation Adjuvant Development and Translation
Lykins, W. R., & Fox, C. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071850 · Cited by 12
Bae, K. H., Shunmuganathan, B. D. O., Zhang, L., Lim, A., Gupta, R., Wang, Y.-M., Chua, B. L., Wang, Y., Gu, Y., Qian, X., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00835-x · Cited by 11
Potential Application of Modified mRNA in Cardiac Regeneration
Wang, A. Y. L., Chang, Y., Chen, K., & Loh, C. Y. Y. (2024) · Cell Transplantation · doi:10.1177/09636897241248956 · Cited by 12
Pharmaceutical strategies for optimized mRNA expression
Shi, Y., Mao, J., Wang, S., Ma, S., Luo, L., & You, J. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122853 · Cited by 11
Kanke, K. L., Rayner, R. E., Bozik, J., Abel, E., Venugopalan, A., Suu, M., Nouri, R., Stack, J. T., Guo, G., Vetter, T. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1069 · Cited by 13
Research progress of mosquito-borne virus mRNA vaccines
Sun, N., Su, Z., & Zheng, X. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101398 · Cited by 11
Stiving, A. Q., Roose, B. W., Tubbs, C. M., Haverick, M. A., Gruber, A., Rustandi, R. R., Kuiper, J. L., Schombs, M. W., Schuessler, H. A., & Li, X. (2025) · npj Vaccines · doi:10.1038/s41541-025-01082-4 · Cited by 15
An mRNA vaccine encoding proteasome-targeted antigen enhances CD8+ T cell immunity
Ling, J., Chen, H., Huang, M., Wang, J., & Du, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.074 · Cited by 11
Bechter, O. E., Loquai, C., Champiat, S., Baurain, J., Grob, J., Utikal, J. S., Rottey, S., Berrocal, A., Hassel, J. C., Arance, A. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1983 · Cited by 11
Dissolving Microneedles for Nucleic Acid Delivery: A Systematic Search, Review, and Data Synthesis
Tobos, C. I., & Woodrow, K. A. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.05.025 · Cited by 13
mRNA Vaccine Technology Beyond COVID-19
Oloruntimehin, E. S., Akinyi, F. T., Paul, M., & Ariyo, O. E. (2025) · Vaccines · doi:10.3390/vaccines13060601 · Cited by 13
Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2
Alimehmeti, I. (2021) · Albanian Journal of Trauma and Emergency Surgery · doi:10.32391/ajtes.v5i1.178 · Cited by 11
Short Oligonucleotides Facilitate Co-transcriptional Labeling of RNA at Specific Positions
Wang, S., Chen, D., Gao, L., & Liu, Y. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00020 · Cited by 11
Metadata
- Authors
- Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D.
- Affiliations
- University of Pennsylvania (US)
- Rockefeller University (US)
- Research Institute for Microbial Diseases, The University of Osaka (JP)
- Corresponding author
- Karikó, Katalin
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 16
- Issue
- 11
- Pages
- 1833-1840
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC2775451
- OpenAlex
- W2058647478
- Cited by
- 1,930
- References
- 30
- Citations by year
- 2026: 249 · 2025: 304 · 2024: 279 · 2023: 249 · 2022: 233 · 2021: 227 · 2020: 97 · 2019: 57 · 2018: 58 · 2017: 40 · 2016: 39 · 2015: 37 · 2014: 17 · 2013: 22 · 2012: 11
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health
- University of California, Riverside
- National Heart, Lung, and Blood Institute (R42HL087688, HL87688)
- National Institute of Allergy and Infectious Diseases (R01AI050484, AI050484)
- National Institute of Neurological Disorders and Stroke (NS29331, R01NS029331)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- pseudouridine, mRNA modification, nucleoside modification, in vitro transcribed mRNA, interferon-alpha, mRNA stability, translational capacity, mRNA vaccines, gene replacement therapy, intravenous delivery
- MeSH terms
- Animals, Cell Line, Genetic Vectors, Humans, Luciferases, Pseudouridine, RNA, Messenger, Transcription, Genetic, Protein Biosynthesis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
